You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 10, October 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correspondence
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Deep Brain Stimulation
 •Movement Disorders
 •Parkinson Disease/ Parkinsonian Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Pallidal vs Subthalamic Deep Brain Stimulation for Parkinson Disease: Winner and Loser or a Sharing of Honors?

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The delightfully illustrated and timely editorial1 on the "rematch" between globus pallidus interna (GPi) and subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson disease was of special interest to our group, which just published a further contribution on this issue based on a nonrandomized study.2 The confirmation by Anderson and colleagues,3 in the only randomized, blinded comparative study to date, that STN and GPi DBS are equally effective in relieving motor symptoms and levodopa-induced dyskinesia at 1 year challenges the widely held assumption that STN is a superior target. They observed greater improvements in bradykinesia and higher levodopa dose reduction in their STN group but without significance (P>.05). These results require confirmation in wider studies over a longer term.

In an open study with similar sample size and follow-up, we also found no differences in main clinical variables between targets, although the greater percentage reduction of levodopa . . . [Full Text of this Article]

AUTHOR INFORMATION

Adolfo Minguez-Castellanos, MD, PhD; Francisco Escamilla-Sevilla, MD, PhD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Pallidal vs Subthalamic Deep Brain Stimulation for Parkinson Disease: Winner and Loser or a Sharing of Honors?—Reply
Penelope Hogarth, Valerie Anderson, and John Hammerstad
Arch Neurol. 2005;62(10):1643.
EXTRACT | FULL TEXT  

Subthalamic Nucleus vs Globus Pallidus Interna Deep Brain Stimulation, the Rematch: Will Pallidal Deep Brain Stimulation Make a Triumphant Return?
Michael S. Okun and Kelly D. Foote
Arch Neurol. 2005;62(4):533-536.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.